HomeNews and media

News & media.

Company announcements, scientific milestones, research perspectives and relevant media coverage.

Research perspectives.

Two researchers in lab coats and hairnets reviewing molecular data on a monitor , PNB Webadmin

The Future of Clinical Research in India: Opportunities and Growth Prospects

Clinical research in India is poised for an era of exponential growth, presenting a landscape rich with potential opportunities. As the global hub for pharmaceutical and biotech research, India stands at the cusp of transformative advancements in the clinical research domain. In this blog, we will take a brief look at the various aspects in which India is advancing on the pharmaceutical frontier.

A scientist in a full protective suit working at a laboratory computer , PNB Webadmin

Global Impact: How Indian Biopharmaceutical Companies are Changing Medicine

The landscape of Biopharmaceutical companies in India stands as a testament to the transformative power of innovation in medicine by the nation. These entities have redefined the norms of drug discovery and development, showcasing their prowess on a global stage through remarkable advancements. In this blog, we will take a brief look at various noticeable advancements and breakthroughs made from within the nation.

A pipette releasing liquid into a row of sample tubes , PNB Webadmin

The Role of Molecule Research in India's Pharmaceutical Landscape

India has been a global centre for medicine in recent decades, and molecular research has played a critical role in this amazing success story. A key component of India’s pharmaceutical industry, molecules research is the process of finding and creating new medications. It drives innovation, economic expansion, and the development of global healthcare solutions.

, PNB Webadmin

The Rise of Biotech Companies in India: A Success Story

India’s biotechnology industry has experienced a spectacular upsurge in the last several years, making it a global success story. The combination of biology and technology, or biotechnology, is a broad field with applications in everything from environmental protection to agriculture and healthcare. A number of variables have combined to propel this change and establish India as a major centre for biotech innovation.

, PNB Webadmin


Balacovin: Kerala firm PNB Vesper Life gets nod for phase 3 clinical trial of Covid drug (opens in a new tab)

A Covid-19 drug manufactured by Kerala-based company, PNB Vesper, has received nod by DCGI to conduct Phase 3 clinical trials. The company will be conducting a nationwide multi-centred clinical trial of the drug- PNB-001 (GPP-BALACOVIN), on Covid-19 patients who are …

, PNB Webadmin


PNB Vesper gets DCGI nod to begin phase III trials for PNB 001/GPP-Balacovin for Covid-19 treatment (opens in a new tab)

PNB Vesper, a leading Kerala-based life sciences company received permission from the DCGI and entering into the final phase 3 clinical trials. After a detailed deliberation by the Subject Expert Committee (SEC) on the phase 2 clinical trial results of …

, PNB Webadmin


PNB Vesper gets DCGI nod to conduct Ph III trials on COVID-19 drug (opens in a new tab)

Kerala-based pharmaceutical organization PNB Vesper has received DCGI permission to conduct the final phase 3 clinical trials. After a detailed deliberation by the Subject Expert Committee (SEC) on the Phase 2 Clinical Trial results of PNB-001 (GPP-BALACOVIN), the company has …

, PNB Webadmin


PNB Vesper to conduct Phase III clinical trials on covid drug, gets DCGI nod (opens in a new tab)

The Phase 3 trial will be conducted on a large patient population in 12 hospitals all over India. GPP- BALACOVIN is a novel and safe drug that possesses significant efficacy to save the hospitalised patients with oxygen support, from the …

, PNB Webadmin

DCGI allows PNB Vesper Life Science to conduct phase-III clinical trials on PNB 001/GPP-BALACOVIN to treat COVID-19 (opens in a new tab)

PNB Vesper has received permission from the Drugs Controller General of India (DCGI) to enter into the phase-III clinical trials of PNB 001/GPP-BALACOVIN, the company said in a statement. After a detailed deliberation by the Subject Expert Committee (SEC) on …

, PNB Webadmin


PNB Vesper completes COVID-19 Phase 2 Clinical Trial (opens in a new tab)

Kerala-based life sciences company PNB Vesper announced that it has successfully completed the COVID-19 Phase 2 Clinical Trials and submitted the final report of its proprietary drug PNB-001 (GPP-Baladol) to the Drug Controller General of India (DCGI). GPP-Baladol is a …

, PNB Webadmin


Kochi firm PNB Vesper Life Sciences completes phase 2 clinical trial of coronavirus drug (opens in a new tab)

Kochi-based PNB Vesper Life Sciences NSE 1.17 % has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency …

, PNB Webadmin


Kochi firm PNB Vesper Life completes phase 2 clinical trial of Covid drug (opens in a new tab)

The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use. The …

, PNB Webadmin

PNB Vesper provides potential option to save hospitalised COVID-19 patients globally (opens in a new tab)

PNB Vesper, a leading Kerala based life sciences company, has announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General …

, PNB Webadmin


PNB Vesper announces its successful competition of phase-2 trials of GPP-Baladol in Covid patients (opens in a new tab)

PNB Vesper, a leading Kerala based Life Sciences Company, today announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. PNB Vesper, a Kerala based Life Science Company has successfully …

, PNB Webadmin

PNB Vesper completes Phase 2 of clinical trials of GPP-Baladol on COVID-19 patients (opens in a new tab)

PNB Vesper, a Kerala-based life sciences company, announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General of India (DCGI) …

, PNB Webadmin


Indian firm PNB Vesper completes Phase II Covid-19 drug trials (opens in a new tab)

India-based life sciences company PNB Vesper has reportedly completed the Phase II clinical trials of its proprietary drug, PNB-001 (GPP-Baladol), on Covid-19 patients. In all the initial preclinical studies, the drug has demonstrated positive results, IANS reported. In addition, it …

, PNB Webadmin


Life sciences firm PNB Vesper successfully completes Phase 2 trials of Covid-19 drug (opens in a new tab)

PNB Vesper, a leading Kerala-based life sciences company, on Thursday announced that it has successfully completed the Phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on Covid-19 patients. The company had received approval from the Drug Controller General …

, PNB Webadmin


PNB Vesper Obtains Permission to Test its New Chemical Entity PNB 001 in COVID-19 Patients (opens in a new tab)

PNB Vesper life science Pvt Ltd, is a leading Indian Pharma Research company with a vision to “work towards a healthier World by developing novel, safe, and affordable medicines to prevent and treat unmet medical needs”. PNB Vesper has today …

, PNB Webadmin

PNB Vesper Life Sciences’ ‘new chemical entity’ okayed for mid-stage Covid-19 trial (opens in a new tab)

In a potentially significant development for the pharmaceutical industry, a new drug developed by a Kochi-based firm has been given the green light to move to mid-stage trials on Covid-19 patients. If proven effective, the drug, GPP-Baladol, would be the …

, PNB Webadmin

Indian Pharma company gets DCGI nod for human trial of new COVID-19 drug, Baladol (opens in a new tab)

Amid the raging coronavirus pandemic, PNB Vesper Life Science Private Limited on Friday received approval from the Drug Controller General of India to conduct the clinical trial of their drug on COVID-19 patients. Speaking to IANS about the breakthrough innovation, …

, PNB Webadmin


Kochi-based firm gets nod to start clinical trial of Covid drug (opens in a new tab)

PNB Vesper Life Science Pvt Ltd, a Kochi-based pharma research company, has received approval from the Drugs Controller General of India (DCGI) to conduct the Phase 2b clinical trial of its proprietary drug PNB-0001, named GPP-Baladol, among Covid-19 patients.PNB Vesper …

, PNB Webadmin

Kochi firm gets nod to test its drug on Covid-19 patients (opens in a new tab)

received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2b clinical trial of their propriety drug PNB-001 (GPP-Baladol) in treating Covid-19 patients. PNB 001 may be the first new chemical entity in the world for …

, PNB Webadmin


New Covid-19 drug gets DCGI’s nod for human trial (opens in a new tab)

New Delhi: Amid the raging coronavirus pandemic, PNB Vesper Life Science Private Limited on Friday received approval from the Drug Controller General of India to conduct the clinical trial of their drug on Covid-19 patients. Speaking to IANS about the …

, PNB Webadmin


Covid-19: PNB Vesper Life Science drug approved for phase 2b clinical trials (opens in a new tab)

Leading Indian pharma research company PNB Vesper Life science has received approval from the Drug Controller General of India (DCGI) to conduct phase-2b clinical trial of its propriety drug PNB-001 (GPP-Baladol) for testing in Covid-19 patients. PN Balaram, CEO of …

, PNB Webadmin


PNB Vesper gets DCGI nod to test its experimental drug on Covid-19 patients (opens in a new tab)

PNB Vesper, a Kochi-based life sciences company, on September 11 said it has received approval from the Drugs Controller General of India (DCGI) to conduct the Phase 2b clinical trial of their propriety drug PNB-001 (GPP-Baladol) on COVID-19 patients. The …

, PNB Webadmin


New Indian Covid-19 drug gets nod for human trials (opens in a new tab)

The Indian Pharma Research company claimed that if their propriety drug PNB-001 – Baladol – works successfully in Covid-19 patients, it would be the “first new chemical entity in the world for treatment of the disease”. The drug has shown …

, PNB Webadmin

PNB Vesper Gets Nod to Begin Phase-2 Clinical Trials for Covid-19 Drug (opens in a new tab)

City-based pharma research firm PNB Vesper has secured the drug controller’s permission to launch phase-II clinical trials for a potential COVID-19 drug — making it the first in the world to begin such trials for a new chemical entity, a …

Media & communications.

Journalists and editors can reach the company directly at info@pnbvesper.com.

Contact PNB Vesper